Cancer genome-sequencing study design

Nature Reviews Genetics

Volumn 14, Issue 5, 2013, Pages 321-332

  Mwenifumbo, Jill C ^a   Marra, Marco A ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN RET;

ACUTE GRANULOCYTIC LEUKEMIA; ADENOCARCINOMA; ALGORITHM; BIOINFORMATICS; BREAST CANCER; CANCER PREVENTION; COHORT ANALYSIS; COLORECTAL CANCER; DNA LIBRARY; GENE LOCUS; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; MELANOMA; MULTIPLE MYELOMA; NEOPLASM; NEUROBLASTOMA; PANCREAS CANCER; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; REVIEW; SIGNAL TRANSDUCTION;

GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; NEOPLASMS; RESEARCH DESIGN; SEQUENCE ANALYSIS, DNA; TRANSCRIPTOME;

EID: 84876527918     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg3445     Document Type: Review

References (105)

1. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719-724 (2009).
2. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
3. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931-945 (2004).
4. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
5. Battelle Technology Partnership Practice. Economic impact of the Human Genome Project: how a $3.8 billion investment drove $796 billion in economic impact, created 310, 000 jobs, and launched the genomic revolution. battelle.org [online], http://www.battelle.org/docs/default-document-library/ economic-impact-of-the-human-genome-project.pdf?sfvrsn=2 2011).
6. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genet. 42, 181-185 (2010) (2011).
7. Sneeringer, C. J. et al. Coordinated activities of wildtype plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980-20985 (2010).
8. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
9. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
10. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
11. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
12. Northcott, P. A. et al. Medulloblastomics: the end of the beginning. Nature Rev. Cancer 12, 818-834 (2012).
13. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nature Rev. Genet. 11, 685-696 (2010).
14. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009).
15. Link, D. C. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305, 1568 (2011).
16. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
17. Jones, S. J. et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 11, R82 (2010).
18. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
19. Pleasance, E. D. et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196 (2009).
20. Pleasance, E. D. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184-190 (2009).
21. Lee, W. et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465, 473-477 (2010).
22. Levy, S. et al. The diploid genome sequence of an individual human. PLoS Biol. 5, e254 (2007).
23. Wheeler, D. A. et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 452, 872-876 (2008).
24. Wang, J. et al. The diploid genome sequence of an Asian individual. Nature 456, 60-65 (2008).
25. Bentley, D. R. et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456, 53-59 (2008).
26. Pelak, K. et al. The characterization of twenty sequenced human genomes. PLoS Genet. 6, e1001111 (2010).
27. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012).
28. Bass, A. J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genet. 43, 964-968 (2011).
29. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
30. Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nature Genet. 44, 760-764 (2012).
31. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001).
32. Ajay, S. S., Parker, S. C. J., Ozel Abaan, H., Fuentes Fajardo, K. V. & Margulies, E. H. Accurate and comprehensive sequencing of personal genomes. Genome Res. 21, 1498-1505 (2011).
33. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
34. Turajlic, S. et al. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22, 196-207 (2011).
35. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
36. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
37. Peña-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nature Genet. 44, 751-759 (2012).
38. Ng, C. K. et al. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J. Pathol. 226, 703-712 (2012).
39. Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005-1010 (2009).
40. Kloosterman, W. P. et al. Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. Genome Biol. 12, R103 (2011).
41. McBride, D. J. et al. Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J. Pathol. 227, 446-455 (2012).
42. Campbell, P. J. et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nature Genet. 40, 722-729 (2008).
43. Muzny, D. M. et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
44. Korbel, J. O. et al. Paired-end mapping reveals extensive structural variation in the human genome. Science 318, 420-426 (2007).
45. Onishi-Seebacher, M. & Korbel, J. O. Challenges in studying genomic structural variant formation mechanisms: the short-read dilemma and beyond. BioEssays 33, 840-850 (2011).
46. Simpson, J. T. et al. ABySS: a parallel assembler for short read sequence data. Genome Res. 19, 1117-1123 (2009).
47. Fullwood, M. J., Wei, C.-L., Liu, E. T. & Ruan, Y. Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res. 19, 521-532 (2009).
48. Medvedev, P., Stanciu, M. & Brudno, M. Computational methods for discovering structural variation with next-generation sequencing. Nature Methods 6, S13-S20 (2009).
49. Hillmer, A. M. et al. Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res. 21, 665-675 (2011).
50. Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423-425 (2012).
51. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
52. Lee, E. et al. Landscape of somatic retrotransposition in human cancers. Science 337, 967-971 (2012).
53. Welch, J. S. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305, 1577 (2011).
54. Weiss, G. J. et al. Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma. PLoS ONE 7, e37029 (2012).
55. Tao, Y. et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc. Natl Acad. Sci. USA 108, 12042-12047 (2011).
56. Bueno, R. et al. Second generation sequencing of the mesothelioma tumor genome. PLoS ONE 5, e10612 (2010).
57. Totoki, Y. et al. High-resolution characterization of a hepatocellular carcinoma genome. Nature Genet. 43, 464-469 (2011).
58. Demeure, M. J. et al. Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. Genome Med. 4, 56 (2012).
59. Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337-342 (2012).
60. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
61. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
62. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
63. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature Genet. 44, 251-253 (2012).
64. Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497-2506 (2011).
65. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
66. Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413 (2010).
67. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011).
68. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012).
69. Pugh, T. J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106-110 (2012).
70. Sathirapongsasuti, J. F. et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 27, 2648-2654 (2011).
71. Karakoc, E. et al. Detection of structural variants and indels within exome data. Nature Methods 9, 176-178 (2012).
72. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
73. Ruan, Y. et al. Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using paired-end ditags (PETs). Genome Res. 17, 828-838 (2007).
74. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-seq. Nature Methods 5, 621-628 (2008).
75. Roberts, K. G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22, 153-166 (2012).
76. Jones, D. T. W. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100-105 (2012).
77. Hammerman, P. S. et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
78. Morin, R. D. et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res. 18, 610-621 (2008).
79. Wang, Z., Gerstein, M. & Snyder, M. RNA-seq: a revolutionary tool for transcriptomics. Nature Rev. Genet. 10, 57-63 (2009).
80. Dees, N. D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
81. Vaske, C. J. et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-i245 (2010).
82. Hawkins, R. D., Hon, G. C. & Ren, B. Next-generation genomics: an integrative approach. Nature Rev. Genet. 11, 476-486 (2010).
83. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
84. Ju, Y. S. et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22, 436-445 (2011).
85. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Rev. Genet. 8, 286-298 (2007).
86. Barski, A. et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837 (2007).
87. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322 (2009).
88. Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329-334 (2012).
89. Cheung, N.-K. V. et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307, 1062-1071 (2012).
90. Molenaar, J. J. et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589-593 (2012).
91. Collins, C. C. et al. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol. Cancer Ther. 11, 775-783 (2012).
92. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
93. Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59-71 (2012).
94. Sung, W.-K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nature Genet. 44, 765-769 (2012).
95. Klein, G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc. Natl Acad. Sci. USA 76, 2442-2446 (1979).
96. Castoe, T. A., De Koning, A. P. J. & Pollock, D. D. Adaptive molecular convergence: molecular evolution versus molecular phylogenetics. Commun. Integr. Biol. 3, 67-69 (2010).
97. Berger, M. F. et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506 (2012).
98. Kimchi-Sarfaty, C. et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315, 525-528 (2007).
99. Pagani, F., Raponi, M. & Baralle, F. E. Synonymous mutations in CFTR exon 12 affect splicing and are not neutral in evolution. Proc. Natl Acad. Sci. USA 102, 6368-6372 (2005).
100. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
101. Wu, C. et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J. Pathol. 227, 53-61 (2012).
102. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
103. Walter, M. J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090-1098 (2012).
104. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283-4288 (2008).
105. Greenman, C., Wooster, R., Futreal, P. A., Stratton, M. R. & Easton, D. F. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 173, 2187-2198 (2006).